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Myeloid proliferative neoplasm with
eosinophiliaThe 2008World Health Organization (WHO) classiﬁcation of tumors of hematopoietic and lymphoid tissues in-
troduced a category for myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA,
PDGFRB or FGFR1. Many of these patients are responsive to tyrosine kinase inhibitor (TKI) therapy. In this case
report, we report a unique case of chronic eosinophilic leukemia with novel t(5;12)(q23-31;p13)/ETV6-ACSL6
gene fusion, in which patient was resistant to TKI therapy. This important ﬁnding is a novel addition to the
above entity in WHO 2008 classiﬁcation. The ACSL6 gene encodes a long-chain acyl-CoA synthetase, an enzyme
that plays an essential role in lipidmetabolism and ATP generation pathways in cells. The ETV6-ACSL6 rearrange-
ment is present in diverse types of hematopoieticmalignancies. As yet, it is not clear how ACSL6, a gene involved
in fatty acid synthesis, contributes to clonal expansion ofmyeloid progenitor cells. Therefore, elucidating the con-
tribution of ACSL6 to leukemogenesis may allow the development of novel treatment for those resistant to TKI
therapy.d Lab
V Stre
. This© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Clonal eosinophilia is frequently associated with myeloid neo-
plasms. Cytogenetic analysis has identiﬁed four distinct recurrent
breakpoint clusters that target PDGFRA at 4q12, PDGFRB at 5q31-33,
FGFR1 at 8p11-12 and JAK2 at 9p24. As a consequence of balanced re-
ciprocal translocations or rare insertions or complex translocations, fu-
sion genes similar to FIP1L1-PDGFRA are created, including ETV6-
PDGFRB in t(5;12)(q31-33;p13), ZNF198-FGFR1 in t(8;13)(p11;q12)
or PCM1-JAK2 in t(8;9)(p11;p24). The 2008World Health Organization
(WHO) classiﬁcation of tumors of hematopoietic and lymphoid tissues
introduced a new category for myeloid and lymphoid neoplasms with
eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Many of
these cases present as a myeloproliferative neoplasm, usually with eo-
sinophilia [1].oratory Medicine, Univer-
et, Sacramento, CA 95817,
is an open access article underTranslocations involving band 12p13 are one of the most common
chromosomal abnormalities in leukemia and myeloproliferative/
myelodysplastic disorders. These translocations frequently result in re-
arrangements of the ETV6 gene. ETV6 fuses to diverse (at least 30 part-
ner) genes in myeloid neoplasms [2]. One of the partner genes is ACSL6
(ACS2 – acyl-CoA synthetase long-chain family member 6), with which
ETV6 can rearrange with and lead to cell transformation and leukemo-
genesis. The ACSL6 gene encodes a long-chain acyl-CoA synthetase
that catalyzes the formation of acyl-CoA from fatty acids, ATP, and CoA
[3]. ACSL6 is predominantly expressed in the bone marrow (BM), fetal
liver and brain [4], and it plays an essential role in lipid metabolism
[3,5]. Several transcript variants encoding different isoforms have been
identiﬁed for this gene [5].
The t(5;12)(q31;p13) has been described as a recurrent transloca-
tion inducing an ETV6-ACSL6 fusion gene and occurring in variety of
myeloidmalignancies, often associatedwith eosinophilia [4,6,7]. Almost
10 years ago, six cases of t(5;12)(q23-31;p13) with ETV6-ACSL6 gene
fusionwere summarized in Leukemia, including acutemyeloid leukemia
(AML), chronic myeloid leukemia (CML), acute eosinophilic leukemia
(AEL) and polycythemia vera (PV) [7]. Here, we report a case of
t(5;12)(q31;p13) translocation with ETV6-ACSL6 rearrangement in a
patient with chronic eosinophilic leukemia (CEL).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Marked eosinophilia is detected in patient's peripheral blood smear (a) and bone marrow core biopsy (b). Fluorescence in situ hybridization analysis (FISH) of rearrangements of
FIP1/CHIC2/PDGFRA, 5p33.1/PDGFRB, 8p11/FGFR1 and 16q22/CBFB is negative (c). Representative G-banded karyotyping reveals translocation of chromosomes 5 and 12 from peripheral
blood cells at metaphases. The breakpoints are identiﬁed as 5q31 and 12p13 (arrows) (d).
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A 52-year-old man presented with progressive eosinophilia for two
years. His initial eosinophilia was mild, with absolute eosinophils of
2400/mm3, but the absolute eosinophil count increased to 13,300/
mm3 two years later. This was associatedwithmild normocytic anemia,
normal platelet count and no neutropenia or monocytosis. The patient
complained of fatigue andmuscle pain. Physical examination and imag-
ing studies showed no organomegaly or lymphadenopathy. An exten-
sive workup for infectious diseases was negative for trichinosis,
strongyloides, toxoplasma, HIV, schistosomiasis and parasitic infection.
The peripheral blood smear showed leukocytosis with marked eosino-
philia, mild basophilia and mild normocytic, normochromic anemia
(Fig. 1a). Bone marrow biopsy revealed a hypercellular (~90% cellulari-
ty)marrowwithmarked eosinophilia. No increase in immaturemyeloid
precursors, blasts or basophils was detected. Therewas no overt dyspla-
sia in the remaining trilineage hematopoiesis (Fig. 1b). No abnormal
mast cells were detected by staining of CD117, CD2, CD25 and tryptase
immunostains. Florescence in situ hybridization (FISH) forMDSmarkers
[−5/del(5q),−7/del(7q), +8 and del(20q)], t(9;22)(q34;q11)/BCR/
ABL1, t(15;17)(q24;q21)/PML-RARA, t(8;21)(q22;q22)/RUNX1T1-
RUNX1, and inv(16)(p13.3q22)/CBFB was negative. FISH was also neg-
ative for rearrangements of FIP1L1/CHIC2/PDGFRA, 5p33.1/PDGFRB,
8p11/FGFR1 and 16q22/CBFB (Fig. 1c). No c-KIT (D816V) mutation or
T cell receptor gamma gene rearrangement was detected. Metaphase
cytogenetic analysis on the bone marrow aspirate detected a
t(5;12)(q31;p13) translocation in 9/20 (45%) metaphases (Fig. 1d).
ETV6-ACSL6 gene fusion was further conﬁrmed by FoundationOne™
Heme assay (Foundation Medicine, Cambridge, MA), a next-generation sequencing (NGS) based assay. The current assay utilizes
DNA sequencing to interrogate 405 genes as well as selected introns
of 31 genes involved in rearrangements, in addition to RNA sequencing
of 265 genes. Targeted RNA-seq found 246 reads supporting the
fusion event: fusion: 5′-ETV6(ex1-1 NM_001987)-ACSL6(ex2-21
NM_015256). No other fusion transcripts were identiﬁed. Therefore,
a diagnosis of CEL, NOS with t(5;12)(q31;p13) resulting in a ETV6-
ACSL6 gene fusion was rendered. Pending the NGS data, the patient
was treated for 3 months with imatinib, but developed progressive
anemia without improvement in the leukocytosis and eosinophilia.
After conﬁrming the ETV6-ACSL6 fusion, therapy was changed to hy-
droxyurea, which led to an improvement in eosinophils, anemia and
clinical symptoms. Allogeneic stem cell transplant is being
considered.
3. Discussion
Yagasaki et al. identiﬁed an ETV6-ACSL6 chimeric gene in three pa-
tients with t(5;12)(q31;p13), including refractory anemia with excess
blasts (RAEB) with basophilia, AML and AEL [4]. Different fusion genes
were identiﬁed by cytogenetic and FISH analysis in these patients: a
short in-frame fusion of exon 1 of ETV6 to the 3′UTR of ACSL6, an out-
of-frame fusion of exon 2 of ETV6 to exon 11 of ACSL6, and an out-of-
frame fusion of exon 1 of ETV6 to exon 1 of ACSL6 [4]. FISH with bacte-
rial artiﬁcial chromosomes (BACs) speciﬁc probes for the ETV6 and
ACSL6 genes were performed on two patients with t(5;12)(q31;p13)-
associated PV and demonstrated the involvement of ETV6 and the 5′ re-
gion of the ACSL6 in the translocation [7]. In the current case, FISH for
t(5;12)(q31;p13) was negative, most likely due to PDGFRB (5p33.1)
Table 1
Genomic alteration detected in this patient using clinical next-generation sequencing (NGS) by FoundationOne™ Heme.
Genomic
alteration
detected
Normal gene function Hematological disorders caused Other tumors caused
BRIP1
W1217*
DNA repair
Chromosome stability maintenance
Fanconi anemia [11] Breast, ovarian and cervical cancer
NF1
I526S
Key regulator of the RAS signaling pathway Juvenile myelomonocytic leukemia
MDS
Sarcoma, glioma, breast tumor and NET
U2AF1
S34F
Encodes a pre-mRNA splicing factor required for
accurate 3′ splice site selection
MDS, AML, CMML and leukemic
transformation of MPN [12]
Lung adenocarcinomas
ETV6
ETV6-ACSL6
fusion
Encodes an ETS family transcription factor required
for hematopoiesis
Various hematopoietic malignancies
including leukemia and MDS [13]
Secretory breast cancer, papillary thyroid carcinomas
associated with radiation [14,15]
MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasms; AML: acute myeloid leukemia; CMML: chronic myelomonocytic leukemia; NET: Neuroendocrine tumor.
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Therefore, detection of the rearrangement was missed by this probe.
RNA-seq showed the current rearrangement resulted in an out-of-
frame fusion of ETV6 exon 1 and ACSL6 exons 2–21. This particular rear-
rangement to our knowledge is novel and has not been previously re-
ported. This out-of-frame fusion would most likely lead to a frameshift
with truncated fusion product. Similar rearrangements involving out-
of-frame fusions of ETV6 exon 1 to ACSL6 have been reported in the
above ﬁve cases [4,7]. These observations suggest that the disruption
of ETV6 and ACSL6 may lead to the pathogenesis of hematological ma-
lignancies with t(5;12)(q31;p13).
Generation of out-of-frame fusions, as in ETV6-ACSL6, can
lead to functional consequences. Molecular analysis of these
fusion genes leads to multiple proposed mechanisms of
leukemogenesis including loss of function of the fusion gene,
affecting ETV6 and/or ACSL6 gene [4], and, loss of the
untranslocated ETV6 and activation of a proto-oncogene in the
vicinity of a chromosomal translocation [7]. An example is inter-
leukin 3 (IL-3, which is located near the breakpoint at 5q31).
When activated, IL-3 promotes proliferation and differentiation
of various hematopoietic cell lineages. Constitutive activation
and dysregulated expression of IL-3 lead to a marked cell prolif-
erative state, which can explain the eosinophilia observed in the
majority of cases with t(5;12)(q31;p13) [8–10,16], including the
current case. The ETV6-ACSL6 rearrangement can be the driving
mutation of leukemogenesis of CEL although detailed molecular
mechanisms have not been determined. Besides the ETV6-ACSL6
fusion, other genomic alterations were identiﬁed including
BRIP1 (DNA repair/chromatin stability), NF1 (tumor suppressor
gene), U2AF1 (RNA splicing) (Table 1). The ﬁndings further
conﬁrm that leukemia may develop as the consequence of an
array of molecular alterations that disrupts many facets of hema-
topoietic precursor cell development to induce leukemia trans-
formation. These processes may include the regulation of cell
proliferation, differentiation, self-renewal, survival, cell cycle
checkpoint control, DNA repair and chromatin stability, and cell
dissemination.
In conclusion, we have reported a case of chronic
eosinophilic leukemia, NOS, with a t(5;12)(q31;p13) resulting
in a novel ETV6-ACSL6 gene fusion. Myeloid neoplasms with
PDGFRA, PDGFRB or FGFR1 abnormalities are the most
important groups of diseases in the differential diagnosis of
eosinophilia-associated myeloproliferative neoplasms, as some
of these patients may be responsive to tyrosine kinase inhibitor
(TKI) therapy. Our current report and the ﬁve cases published
previously suggest that ETV6 plays a pivotal role in the regula-
tion of myeloid hematopoiesis, especially at the eosinophilic
progenitor level and therefore, these patients will not be
responsive to TKI. This may represents a distinctive entity tothe previous 2008 WHO classiﬁcation. Further molecular stud-
ies are needed to clarify the underlying mechanism of ACSL6
in leukemogenesis and how aberrant expression of a gene in-
volved in fatty acid synthesis can result in clonal expansion.
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